Abbott Labs SEC Filings

Abbott Laboratories (ABT)1,586 shares of common stock through UBS Financial Services on the NYSE, with an indicated aggregate market value of $203,042 as of the notice. The filing notes that there were 1,738,871,947 shares of common stock outstanding, providing context for the size of the planned sale.

The shares to be sold come from vested restricted stock awards. Three separate restricted stock award vestings dated 02/28/2025 are listed, for 740, 250, and 596 common shares, all acquired from the issuer, with payment dated 11/25/2025 and the nature of payment shown as “N/A.” The notice includes the standard Rule 144 representation that the seller does not know of undisclosed material adverse information about Abbott’s current or prospective operations.

Abbott Laboratories reported that its U.S. and Puerto Rico stock retirement plans will undergo an administrative blackout period. The blackout is being implemented to make several plan administration changes, including switching the recordkeeper, changing the trustee for certain U.S. Plan funds, and changing the custodian for certain P.R. Plan funds.

During the blackout, participants in these plans will not be able to change contribution rates, reallocate or diversify investments (including Abbott common shares), or obtain loans, withdrawals, or distributions from their plan accounts. The blackout is expected to begin on December 24, 2025 at 12 p.m. CST and to end during the week of January 11, 2026.

Abbott also notified its directors and executive officers about the blackout and related restrictions on trading in Abbott common shares under Section 306 of the Sarbanes-Oxley Act and Regulation BTR. Additional information about the blackout, including its actual start and end dates, is available on request from Abbott for two years after it ends.

Abbott Laboratories announced a definitive agreement to acquire Exact Sciences through a cash merger. Each outstanding Exact Sciences common share will be converted at closing into the right to receive $105.00 in cash, subject to customary terms and tax withholding, with Exact Sciences becoming a wholly owned Abbott subsidiary.

The deal is conditioned on approval by holders of at least a majority of Exact Sciences shares, required regulatory clearances including expiration or termination of the Hart-Scott-Rodino waiting period, absence of legal restraints, and satisfaction of representations, covenants, and a no–material adverse effect condition on Exact Sciences. In connection with signing, Abbott obtained a commitment for up to $20,000,000,000 of senior unsecured bridge loans to support the transaction.

Abbott Laboratories filed its Q3 2025 report with steady profit and higher sales. Net sales were $11,369 million, up from $10,635 million a year ago, while diluted EPS held at $0.94. Year‑to‑date, sales reached $32,869 million and diluted EPS rose to $2.70 from $2.38. Operating earnings improved to $2,057 million, supported by Medical Devices growth (notably Diabetes Care and Electrophysiology) and stronger Established Pharmaceuticals, partly offset by lower COVID‑19 testing revenue.

Cash from operations was $6,251 million for the first nine months, funding $1,503 million of long‑term debt repayments and $3,086 million in dividends, with purchases of common shares of $591 million. The company recorded 2025 restructuring charges of $197 million and $25 million of asset impairments to streamline diagnostics and devices. Remaining performance obligations were $6.0 billion in Diagnostics and $436 million in Medical Devices. As of September 30, 2025, common shares outstanding were 1,738,871,947.

Abbott Laboratories reported its third-quarter 2025 results, noting that the information was furnished under Item 2.02 and accompanied by a press release as Exhibit 99.1.

The company highlighted the use of non-GAAP financial measures to evaluate ongoing business performance. These measures adjust for items that can be unusual or unpredictable, including acquisition-related expenses, restructuring actions, fair value changes in contingent consideration, certain regulatory costs, adjustments tied to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit from resolution of prior-year tax positions, and excess tax benefits from share-based compensation. They also exclude intangible amortization expense to show results excluding these costs. Management believes these metrics provide useful insight for investors, while cautioning they should be considered alongside GAAP results.

John G. Stratton, a director of Abbott Laboratories (ABT), had 293 stock-equivalent units credited on 09/30/2025 under a grantor trust that converts director fees into units that track Abbott share returns. The units are valued at $133.94 each in this filing and the reporting person’s total beneficial ownership after the transaction is reported as 12,663 shares or share equivalents. The filing explains these units are paid in cash generally at age 65 or upon retirement from the board and that the balance includes units from a dividend reinvestment feature. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Patricia Paola Gonzalez, a director of Abbott Laboratories (ABT), had a non-derivative transaction on 09/30/2025 that credited 246 stock equivalent units at an indicated per-share reference of $133.94. After the reported transaction, the filing shows she beneficially owned 4,922 shares/stock-equivalent units. The filing explains these credits represent director fees placed into a stock equivalent unit account under a director grantor trust, which are paid in cash generally at age 65 or upon retirement from the board and earn the same return as if invested in Abbott shares. The reported Form 4 was signed via attorney-in-fact on 10/02/2025.

Robert J. Alpern, a director of Abbott Laboratories (ABT), reported a transaction dated 09/30/2025 on a Form 4. The filing shows an acquisition of 58 common share equivalents recorded at $133.94 per share and a post-transaction beneficial balance of 10,300 stock-equivalent units. The filing notes these units represent director fees credited to a grantor trust that mirror Abbott share returns and are generally paid in cash at age 65 or upon board retirement; the balance also includes units from a dividend reinvestment feature. The Form 4 was signed on behalf of Mr. Alpern by an attorney-in-fact on 10/02/2025.

Abbott Laboratories reporting person John A. McCoy Jr., Vice President and Controller, is disclosed as selling 79 common shares on 09/01/2025 at a price of $132.66 per share. After the reported disposition, Mr. McCoy beneficially owns 20,982 common shares directly. The filing also notes an indirect interest in Abbott shares held in a profit sharing/stock retirement trust, with the balance in that trust stated as of September 1, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. McCoy on 09/03/2025.